EvolveImmune Therapeutics
Yanhuai (Richard) Ding is an experienced professional in the field of process development and manufacturing operations, currently serving as Senior Director CMC DS at EvolveImmune Therapeutics. Previous roles include Director and Head of Purification Process Development at Biogen, Director of Downstream Process Development, MSAT, and Manufacturing Operations at AnaptysBio, and Principal Scientist in Downstream Process Development at Thermo Fisher Scientific. At Therapeutic Proteins International, LLC, Yanhuai (Richard) Ding held the position of Sr. Manager, leading Downstream Process Development. Academic credentials include a Sr. Post Doctorial Fellowship in Protein Chemistry from the University of Massachusetts Amherst and a Post Doctorial Fellowship in Biochemistry and Molecular Biology from Penn State University.
This person is not in any offices
EvolveImmune Therapeutics
2 followers
EvolveImmune Therapeutics is a next-generation immunotherapy platform company based in Farmington and Branford, CT. Building upon research that originates from the Sidi Chen Lab at Yale University, EvolveImmune is leveraging a novel in vivo target discovery platform to develop a broad portfolio of first-in-class molecules for unmet needs in oncology and autoimmune diseases.